| __timestamp | Grifols, S.A. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 1656170000 | 60987000 |
| Thursday, January 1, 2015 | 2003565000 | 125542000 |
| Friday, January 1, 2016 | 2137539000 | 210460000 |
| Sunday, January 1, 2017 | 2166062000 | 275119000 |
| Monday, January 1, 2018 | 2437164000 | 409539000 |
| Tuesday, January 1, 2019 | 2757459000 | 547758000 |
| Wednesday, January 1, 2020 | 3084873000 | 736300000 |
| Friday, January 1, 2021 | 2970522000 | 904200000 |
| Saturday, January 1, 2022 | 3832437000 | 1080300000 |
| Sunday, January 1, 2023 | 4269276000 | 1262200000 |
| Monday, January 1, 2024 | 1530500000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. Over the past decade, Grifols, S.A. and Vertex Pharmaceuticals Incorporated have showcased contrasting trajectories in their cost of revenue. From 2014 to 2023, Grifols, S.A. consistently reported higher costs, peaking at approximately $4.27 billion in 2023, reflecting a 158% increase from 2014. In contrast, Vertex Pharmaceuticals demonstrated a more conservative growth, with costs rising from $61 million in 2014 to $1.26 billion in 2023, marking a 1965% surge. This stark difference highlights Grifols' expansive operations compared to Vertex's strategic scaling. As the industry evolves, these trends underscore the importance of balancing growth with cost efficiency. Investors and stakeholders should keenly observe how these companies adapt to future challenges, ensuring sustainable growth while maintaining fiscal prudence.
Cost of Revenue: Key Insights for Johnson & Johnson and Vertex Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Novartis AG vs Vertex Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Grifols, S.A.
Cost of Revenue Comparison: Gilead Sciences, Inc. vs Grifols, S.A.
Comparing Cost of Revenue Efficiency: Vertex Pharmaceuticals Incorporated vs BeiGene, Ltd.
Who Generates Higher Gross Profit? Vertex Pharmaceuticals Incorporated or Grifols, S.A.
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics AG's Expenses
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Vertex Pharmaceuticals Incorporated and Geron Corporation's Expenses
Cost of Revenue: Key Insights for Vertex Pharmaceuticals Incorporated and Viridian Therapeutics, Inc.
Cost of Revenue Trends: Jazz Pharmaceuticals plc vs Grifols, S.A.
Cost of Revenue Trends: Grifols, S.A. vs ADMA Biologics, Inc.